What kind of economic impact can we expect from recreational cannabis legalization? Contributors to our Policy Options feature series The Economics of Canadian Cannabis join the “potcast” to discuss.

Colin Busby, IRPP research director and co-editor of the series, gives an overview of some of the key economic questions being raised as the Oct.17 legalization date approaches. Allan W. Gregory, professor of economics at Queen’s University, looks at the future of the medical cannabis market. And Rebecca Jesseman, director of policy at the Canadian Centre on Substance Use and Addiction, breaks down the potential health costs of legalization.

Download for free. New episodes every second Wednesday. Tweet your questions and comments to @IRPP or @madihaslam.

Photo: Marijuana plants grow at MedReleaf in Markham, Canada. EPA/WARREN TODA. 

Do you have something to say about the article you just read? Be part of the Policy Options discussion, and send in your own submission. Here is a link on how to do it. | Souhaitez-vous réagir à cet article ? Joignez-vous aux débats d’Options politiques et soumettez-nous votre texte en suivant ces directives.

Download for free. Tweet your questions and comments to @IRPP.

Colin Busby
Colin Busby is director of policy and outreach at HEC Montréal's Retirement and Savings Institute. He was previously a research director at the Institute for Research on Public Policy. Before joining the IRPP, he was the associate director of research at the C.D. Howe Institute, and has also worked at Industry Canada and the United Nations Industrial Development Organization. LinkedIn and Twitter @cbusby_eco.
Allan W. Gregory
Allan W. Gregory is a professor of economics at Queen’s University. His main research interests have been in applied time series issues primarily in finance, international, and forecasting. He is also active in health economics.  
Rebecca Jesseman
Rebecca Jesseman is the director of policy with the Canadian Centre on Substance Use and Addiction, where she has provided expertise in cannabis regulation and drug policy more broadly at the national and international levels for over 13 years.  
More like this